Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Gut-derived molecule shows powerful potential in fighting diabetes
New research reveals that TMA can block a key immune protein known as IRAK4, which is heavily involved in driving inflammation and insulin resistance. By inhibiting this protein, TMA helps restore the body’s sensitivity to insulin, resulting in improved blood-sugar control in laboratory and animal studies.
- By ANI
- New Delhi
- Dec 09, 2025
Scientists have identified a gut-produced molecule that could pave the way for a new generation of diabetes treatments. The compound, Trimethylamine (TMA), is generated when gut bacteria break down choline, a nutrient found in foods such as eggs, fish and meat.
New research reveals that TMA can block a key immune protein known as IRAK4, which is heavily involved in driving inflammation and insulin resistance. By inhibiting this protein, TMA helps restore the body’s sensitivity to insulin, resulting in improved blood-sugar control in laboratory and animal studies.
IRAK4 is known to become overactive in conditions triggered by high-fat diets, leading to chronic inflammation and metabolic imbalance. The study shows that TMA binds to IRAK4 and suppresses this inflammatory chain reaction, helping the body respond more effectively to insulin even under dietary stress.
In experiments on mice, the molecule not only improved insulin sensitivity but also helped protect against severe inflammatory responses such as sepsis suggesting broader therapeutic potential beyond diabetes.
The discovery, driven by a collaboration between international research teams, reinforces the growing understanding of how gut microbes influence metabolic health. Instead of relying solely on traditional drug approaches, scientists are increasingly exploring the body’s own microbiome for future therapies.
Since IRAK4 is already considered an attractive drug target, the findings raise the possibility that TMA-based or TMA-inspired treatments could one day help counter insulin resistance and inflammation with fewer side effects than existing medications.
With type 2 diabetes continuing to rise worldwide, this gut-microbe-derived molecule offers a promising new pathway for tackling one of today’s most widespread metabolic disorders.